Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant - PA: Gender, Sex & Health Research Integration and Innovation

McMaster University

$100,000.00

Characterization of a novel clinical marker of endometriosis.

FY 2013-14

Summary
Endometriosis is a chronic, painful, progressive, inflammatory disease that has a profoundly deleterious effect upon women's role performance, social functioning, emotional well-being, relationships with medical practitioners, vitality, and employment. The annual costs associated with surgically confirmed endometriosis in Canada alone are approximately 1.8 billion dollars. Moreover, the health care costs associated with endometriosis are similar to or greater than other chronic diseases such as Crohn's disease, diabetes, asthma, migraines, and rheumatoid arthritis. Sadly, women with endometriosis experience significant delays of up to 12 years before a definitive diagnosis is achieved. The gold standard for diagnosis remains laparoscopic visualization of endometriotic implants followed by histopathological confirmation of disease. Although risks to patients from laparoscopy are rare, they are significant and women with endometriosis can expect to undergo multiple diagnostic and operative laparoscopies over the course of their disease. Thus, there is an urgent need to identify novel non- or semi-invasive clinical markers of endometriosis. Our preliminary data suggest that the plasma concentrations of BDNF are significantly higher in women with endometriosis compared to healthy controls. Therefore, we hypothesize that this protein is a potentially valuable candidate clinical marker of endometriosis. Consequently, we propose a pre-clinical discovery phase project to better characterize the concentrations of BDNF in the blood as a potentially useful semi-invasive diagnostic test for endometriosis. We further postulate that blood concentrations of BDNF could be used to monitor disease progression and patient response to treatments. We also plan to determine the mechanism(s) underlying the expression of this protein as we think this could also be a potential therapeutic target that we will explore in future applications.
Program
Operating Grant - PA: Gender, Sex & Health Research Integration and Innovation
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
299255
Name
Foster Warren G
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Gender and Health
Theme2
Biomedical
Prcname2
Clinical Investigation - A: Reproduction, Maternal, Child and Youth Health
Projecttitle
Characterization of a novel clinical marker of endometriosis.
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Gender, Sex & Health Research Integration and Innovation
Keyworddelim
Chronic Disease; Diagnostic Markers; Endometriosis; Epidemiology; Estrogens; Fertility; Menstrual Cycle; Pelvic Pain; Reproduction; Women'S Health
Abstract
Endometriosis is a chronic, painful, progressive, inflammatory disease that has a profoundly deleterious effect upon women's role performance, social functioning, emotional well-being, relationships with medical practitioners, vitality, and employment. The annual costs associated with surgically confirmed endometriosis in Canada alone are approximately 1.8 billion dollars. Moreover, the health care costs associated with endometriosis are similar to or greater than other chronic diseases such as Crohn's disease, diabetes, asthma, migraines, and rheumatoid arthritis. Sadly, women with endometriosis experience significant delays of up to 12 years before a definitive diagnosis is achieved. The gold standard for diagnosis remains laparoscopic visualization of endometriotic implants followed by histopathological confirmation of disease. Although risks to patients from laparoscopy are rare, they are significant and women with endometriosis can expect to undergo multiple diagnostic and operative laparoscopies over the course of their disease. Thus, there is an urgent need to identify novel non- or semi-invasive clinical markers of endometriosis. Our preliminary data suggest that the plasma concentrations of BDNF are significantly higher in women with endometriosis compared to healthy controls. Therefore, we hypothesize that this protein is a potentially valuable candidate clinical marker of endometriosis. Consequently, we propose a pre-clinical discovery phase project to better characterize the concentrations of BDNF in the blood as a potentially useful semi-invasive diagnostic test for endometriosis. We further postulate that blood concentrations of BDNF could be used to monitor disease progression and patient response to treatments. We also plan to determine the mechanism(s) underlying the expression of this protein as we think this could also be a potential therapeutic target that we will explore in future applications.
Competitiondate
201309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Foster, Warren G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~